{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:43:02Z","timestamp":1794606182810,"version":"4.9.1"},"reference-count":32,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>CD19 chimeric antigen receptor (CAR) T cells can induce prolonged remissions and potentially cure a significant proportion of patients with relapsed\/refractory large B-cell lymphomas. However, some patients may die of causes unrelated to lymphoma after CAR T-cell therapy. To date, little is known about the nonrelapse mortality (NRM) after CAR T-cell therapy. Using the French DESCAR-T registry, we analyzed the incidence and causes of NRM and identified risk factors of NRM. We report on 957 patients who received standard-of-care axicabtagene ciloleucel (n\u00a0= 598) or tisagenlecleucel (n\u00a0= 359) between July 2018 and April 2022, in 27 French centers. With a median follow-up of 12.4\u00a0months, overall NRM occurred in 48 patients (5.0% of all patients): early (before day 28 after infusion) in 9 patients (0.9% of all patients and 19% of overall NRM), and late (on\/after day 28 after infusion) in 39 patients (4.1% of all patients and 81% of overall NRM). Causes of overall NRM were distributed as follows: 56% infections (29% with non\u2013COVID-19 and 27% with COVID-19), 10% cytokine release syndromes, 6% stroke, 6% cerebral hemorrhage, 6% second malignancies, 4% immune effector cell associated neurotoxicities, and 10% deaths from other causes. We report risk factors of early NRM and overall NRM. In multivariate analysis, both diabetes and elevated ferritin level at lymphodepletion were associated with an increased risk of overall NRM. Our results may help physicians in patient selection and management in order to reduce the NRM after CAR T-cell therapy.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010624","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T12:43:55Z","timestamp":1694004235000},"page":"6589-6598","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":91,"title":["Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5833-6728","authenticated-orcid":false,"given":"Jean","family":"Lemoine","sequence":"first","affiliation":[{"name":"1Department of Hematology, CHU de Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2694-7510","authenticated-orcid":false,"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Benite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-9635","authenticated-orcid":false,"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[{"name":"3Department of Hematology, CHU de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Beauvais","sequence":"additional","affiliation":[{"name":"4Department of Hematology, CHU de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gastinne","sequence":"additional","affiliation":[{"name":"5Department of Hematology, CHU de Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9001-573X","authenticated-orcid":false,"given":"Roberta","family":"Di Blasi","sequence":"additional","affiliation":[{"name":"6Department of Hemato-Oncology, Saint Louis Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Th\u00e9r\u00e8se","family":"Rubio","sequence":"additional","affiliation":[{"name":"7Department of Hematology, CHU Brabois, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8755-5591","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Guidez","sequence":"additional","affiliation":[{"name":"8Department of Hematology, CHU de Poitiers, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Saint Antoine Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene-Olivier","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"10Department of Hematology, CHU de Dijon, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Joris","sequence":"additional","affiliation":[{"name":"11Department of Hematology, CHU d\u2019Amiens, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Castilla-Llorente","sequence":"additional","affiliation":[{"name":"12Department of Hematology and INSERM, UMR 1030, Universit\u00e9 Paris-Saclay, Gustave Roussy Cancer Campus Grand Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[{"name":"13Lymphoid Malignancies, Henri Mondor Hospital, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"14Department of Hematology, Necker Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4460-5939","authenticated-orcid":false,"given":"Michael","family":"Loschi","sequence":"additional","affiliation":[{"name":"15Department of Hematology, CHU de Nice, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0796-7914","authenticated-orcid":false,"given":"Sylvain","family":"Carras","sequence":"additional","affiliation":[{"name":"16Department of Hematology, CHU de Grenoble, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2252-0395","authenticated-orcid":false,"given":"Pierre","family":"Bories","sequence":"additional","affiliation":[{"name":"17Hematology Laboratory, Onco-occitanie Network, Toulouse University Institute of Cancer-Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Fradon","sequence":"additional","affiliation":[{"name":"18LYSARC, The Lymphoma Academic Research Organisation, Lyon-Sud Hospital, Pierre-Benite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4910-476X","authenticated-orcid":false,"given":"Charles","family":"Herbaux","sequence":"additional","affiliation":[{"name":"3Department of Hematology, CHU de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-822X","authenticated-orcid":false,"given":"Pierre","family":"Sesques","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Benite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9840-2128","authenticated-orcid":false,"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[{"name":"19Curie Institute, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"4Department of Hematology, CHU de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"6Department of Hemato-Oncology, Saint Louis Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[{"name":"1Department of Hematology, CHU de Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"issue":"26","key":"2023111415004187700_bib1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023111415004187700_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10254","key":"2023111415004187700_bib3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"7","key":"2023111415004187700_bib4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10343","key":"2023111415004187700_bib5","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"27","key":"2023111415004187700_bib6","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2023111415004187700_bib7","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"2023111415004187700_bib8","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2023111415004187700_bib9","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2023111415004187700_bib10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2023","journal-title":"Haematologica"},{"issue":"18","key":"2023111415004187700_bib11","doi-asserted-by":"crossref","first-page":"18741","DOI":"10.18632\/aging.104058","article-title":"A\u00a0comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy","volume":"12","author":"Cai","year":"2020","journal-title":"Aging"},{"issue":"15 suppl","key":"2023111415004187700_bib12","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2019.37.15_suppl.2540","article-title":"Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS","volume":"37","author":"Anand","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"2023111415004187700_bib13","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2023111415004187700_bib14","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S2352-3026(17)30108-4","article-title":"EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis","volume":"4","author":"Luft","year":"2017","journal-title":"Lancet Haematol"},{"issue":"17","key":"2023111415004187700_bib15","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2023111415004187700_bib16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41409-021-01526-0","article-title":"Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed\/refractory B-cell lymphoma","volume":"57","author":"Li\u00e9vin","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2023111415004187700_bib17","doi-asserted-by":"crossref","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"13","key":"2023111415004187700_bib18","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"2023111415004187700_bib19","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.2337\/dc18-0287","article-title":"Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study","volume":"41","author":"Critchley","year":"2018","journal-title":"Diabetes Care"},{"issue":"11","key":"2023111415004187700_bib20","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1007\/s00125-021-05522-3","article-title":"Diabetes and the risk of hospitalisation for infection: the Atherosclerosis Risk in Communities (ARIC) study","volume":"64","author":"Fang","year":"2021","journal-title":"Diabetologia"},{"issue":"14","key":"2023111415004187700_bib21","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2023111415004187700_bib22","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A\u00a0real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"2023111415004187700_bib23","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/bloodadvances.2021006112","article-title":"Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy","volume":"6","author":"Dahiya","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2023111415004187700_bib24","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1038\/s41375-021-01466-0","article-title":"Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group","volume":"35","author":"Spanjaart","year":"2021","journal-title":"Leukemia"},{"issue":"23","key":"2023111415004187700_bib25","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of COVID-19","volume":"386","author":"Levin","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023111415004187700_bib26","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/s41591-022-01792-5","article-title":"Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies","volume":"28","author":"Bruel","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"2023111415004187700_bib27","doi-asserted-by":"crossref","first-page":"110812","DOI":"10.1016\/j.celrep.2022.110812","article-title":"LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants","volume":"39","author":"Westendorf","year":"2022","journal-title":"Cell Rep"},{"issue":"5","key":"2023111415004187700_bib28","first-page":"475","article-title":"Nirmatrelvir for nonhospitalized adults with COVID-19. Reply","volume":"387","author":"Hammond","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023111415004187700_bib29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe COVID-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023111415004187700_bib30","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2023111415004187700_bib31","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"Horby","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2023111415004187700_bib32","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJMoa2103784","article-title":"Early convalescent plasma for high-risk outpatients with COVID-19","volume":"385","author":"Korley","year":"2021","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6589\/2089071\/blooda_adv-2023-010624-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6589\/2089071\/blooda_adv-2023-010624-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:06:37Z","timestamp":1699956397000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/21\/6589\/497767\/Nonrelapse-mortality-after-CAR-T-cell-therapy-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":32,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,11,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010624","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]}}}